SureTrader SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, Foxwoods Man, drkazmd65
Search This Board:
Last Post: 8/29/2015 10:59:31 AM - Followers: 162 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/



Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
  2. The scientific, clinical, and commercial development of the medicine and
  3. CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  
  2. Teva Pharmaceuticals Industries Ltd.
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  
  3.  
  4. Orient Europharma Co. Ltd.
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  
  5.  
  6. IDC-GP Pharm LLC 
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  
  7.  

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
Wiki
CVM News: Securities Registration: Employee Benefit Plan (s-8) 08/24/2015 04:54:13 PM
CVM News: Quarterly Report (10-q) 08/07/2015 06:26:34 PM
CVM News: CEL-SCI Corporation Reports Third Quarter Fiscal Year 2015 Financial Results 08/07/2015 04:30:00 PM
CVM News: CEL-SCI Reports Record Monthly Patient Enrollment in July for Its Phase 3 Head and Neck Cancer Trial 08/03/2015 09:00:00 AM
CVM News: Biotechnology Stocks Review -- Juno Therapeutics, Amicus Therapeutics, ImmunoGen, CEL-SCI, and Ignyta 07/29/2015 09:15:00 AM
PostSubject
#7169  Sticky Note Definitely an interesting article: drkazmd65 07/27/15 01:22:18 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#7222   CEL-SCI is now knocking at the door of trickledownfacists 08/29/15 10:59:31 AM
#7221   "Dr. Joel Palefsky, world renown anal wart expert dbernet 08/28/15 05:39:17 PM
#7220   As of June 30, 2015, the Company had ducruacuteo11 08/28/15 03:37:21 PM
#7219   The goods: ducruacuteo11 08/28/15 03:13:54 PM
#7218   That info can be obtained in the last Foxwoods Man 08/28/15 06:55:56 AM
#7217   What's the share structure os as and float stockmoneybaby 08/27/15 07:41:34 PM
#7216   Can get the attention on this one but stockmoneybaby 08/27/15 07:40:56 PM
#7215   we need to get on the radar of Turney 08/27/15 06:10:01 PM
#7214   I agree with you but, are the points ducruacuteo11 08/27/15 11:20:49 AM
#7213   ...and 50 thousand restricted shares. Foxwoods Man 08/27/15 09:19:40 AM
#7212   good article but if you read down in Turney 08/27/15 07:19:57 AM
#7211   Great article! At this point, nothing will ducruacuteo11 08/26/15 06:23:58 PM
#7210   Link: Foxwoods Man 08/26/15 04:16:54 PM
#7209   An article on CVM just posted on SmallCapNetwork MsMom1 08/26/15 03:04:34 PM
#7208   If you believe in the company and don't Foxwoods Man 08/26/15 02:49:07 PM
#7207   what would be a good entry point. Seems whynot1790 08/26/15 02:42:13 PM
#7206   Well going by some of the pictures I've pijoe 08/26/15 08:59:54 AM
#7205   stockcharts.com/c-sc/sc?s=CVM&p=D&b=21&g=0&i=p69412508847&r=1361457330369 mick 08/25/15 12:51:42 PM
#7204   I believe this is one of the only ducruacuteo11 08/25/15 11:51:07 AM
#7203   Of course they will use those patients. Foxwoods Man 08/23/15 07:30:45 AM
#7202   Unless they are approved to use patients from trickledownfacists 08/22/15 10:02:39 PM
#7201   The study is trying to prove that Multikine Foxwoods Man 08/22/15 07:23:33 AM
#7200   I don't know anything about the PIII process ducruacuteo11 08/21/15 04:24:42 PM
#7199   Yup...but the "events" are the main focus..I think Foxwoods Man 08/21/15 01:56:08 PM
#7198   O.K. I am back in. Hoping ducruacuteo11 08/21/15 01:54:14 PM
#7197   ..An enlistment of over 30 patients for August Foxwoods Man 08/19/15 06:58:19 AM
#7196   Any enlistment this month over 30 patients is trickledownfacists 08/18/15 05:26:24 PM
#7195   stockcharts.com/c-sc/sc?s=CVM&p=D&yr=1&mn=0&dy=0&i=p37577003074&r=1407023 mick 08/16/15 06:13:42 PM
#7194   That would be nice...can't say I would short Foxwoods Man 08/12/15 06:31:10 AM
#7193   We need a squeeeeze... CEL-SCI (NYSE:CVM) was the target trickledownfacists 08/12/15 01:29:09 AM
#7192   Hoping to see another record enrollment month and trickledownfacists 08/11/15 11:05:41 AM
#7191   stockcharts.com/c-sc/sc?s=CVM&p=D&yr=0&mn=2&dy=0&i=t21771599565&r=1392585 mick 08/08/15 05:35:13 PM
#7190   CEL-SCI Corporation Reports Third Quarter Fiscal Year 2015 trickledownfacists 08/07/15 04:36:40 PM
#7189   I think that the "events" are the main Foxwoods Man 08/03/15 04:08:04 PM
#7188   So,... if they can (at minimum) hold this drkazmd65 08/03/15 02:20:23 PM
#7187   Best number yet. trickledownfacists 08/03/15 11:11:07 AM
#7186   That is a much better number.... Foxwoods Man 08/03/15 10:57:13 AM
#7185   Record enrollment! trickledownfacists 08/03/15 10:44:32 AM
#7184   CEL-SCI Reports Record Monthly Patient Enrollment in July trickledownfacists 08/03/15 10:35:46 AM
#7183   Apparently we hit 33 in July. drkazmd65 08/03/15 09:38:49 AM
#7182   As of June 30th (last report) there have Foxwoods Man 08/03/15 07:14:25 AM
#7181   Yep. Am hoping for more than 30. drkazmd65 08/02/15 09:53:20 PM
#7180   Anything over 30 I'm happy with. trickledownfacists 08/02/15 03:48:37 PM
#7179   July numbers coming. trickledownfacists 08/02/15 02:24:18 PM
#7178   Cel-Sci Corp. Common (CVM) mick 08/01/15 08:01:13 PM
#7177   I just loaded my little boat with the george h 07/30/15 11:41:10 AM
#7176   This is too easy. When you can buy Turney 07/29/15 10:20:20 PM
#7175   Cel-Sci Corp. Common (CVM) mick 07/28/15 01:28:31 PM
#7174   Ok...I am missing the point of that post Foxwoods Man 07/28/15 01:13:30 PM
#7173   http://investorshub.advfn.com/boards/getboards.aspx?searchstr=CVM mick 07/28/15 11:39:12 AM
PostSubject